Biogen Inc.: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

CAMBRIDGE, Mass., Jan. 27, 2022Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa)

Related Keywords

Japan ,Nevada ,United States ,Tokyo ,Cambridge ,Cambridgeshire ,United Kingdom ,Americans ,American ,Walter Gilbert ,Charles Weissmann ,Heinz Schaller ,Dylan Wint ,Ashleigh Koss ,Priya Singhal ,Mike Hencke ,Kenneth Murray ,Linkedin ,Twitter ,Investor Relations Department ,National Coverage Determination ,Brain Health ,Nasdaq ,Centers For Medicare ,Public Relations Department ,Facebook ,Medicaid Services ,Head Of Global Safety Regulatory Sciences ,Eisai Inc ,Cleveland Clinic Lou Ruvo Center ,Eisai Co Ltd ,Alzheimer Disease Cooperative Study ,Exchange Commission ,Youtube ,Head Of Research Development At Biogen ,African American ,Global Safety ,Regulatory Sciences ,Clinical Dementia Rating Sum ,Mild Cognitive Impairment ,Disease Assessment Scale Cognitive Subscale ,Disease Cooperative Study ,Daily Living Inventory ,Cognitive Impairment Version ,Integrated Alzheimer ,Disease Rating Scale ,Mini Mental State Examination ,Neuropsychiatric Inventory ,Amyloid Related Imaging Abnormalities ,Prescribing Information ,Sir Kenneth Murray ,Nobel Prize ,Healthy Lives ,Dementia Platform ,Private Securities Litigation Reform Act ,Media Outside ,Biogen ,Update ,Hase ,Envision ,Confirmatory ,Study ,Aduhelm ,